arrow
P

Patrick M. Moriarty

University of Kansas Medical Center
H指数:51
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Healthcare Professional Awareness and Use of Inflammation-Based Risk Assessment in ASCVD: The CARDIO-INFLAME Survey

医疗专业人员对炎症为基础的风险评估在动脉粥样硬化性心血管疾病中的认知与使用:CARDIO-INFLAME调查

2026-08-290
OAAI
Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

Evinacumab治疗小儿纯合子家族性高胆固醇血症

2024-01-3021
OAAI
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
2023-06-0140
OAAI
Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry
2023-05-0221
OAAI
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

他汀类药物不耐受患者的Bempedoic酸和心血管结局

2023-04-13360
PRE
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

Evinacumab治疗伴或不伴脂蛋白脂肪酶途径突变的严重高甘油三酯血症: 一项2期随机试验

2023-03-0643
OAAI
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes
2022-09-010
OAAI
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia

olezarsen靶向apoc-iii对高甘油三酯血症患者通过NMR测量的脂蛋白大小和颗粒数的影响

2022-09-0127
OAAI
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

脂蛋白 (a) 在动脉粥样硬化性心血管疾病和主动脉瓣狭窄中的作用: 欧洲动脉粥样硬化学会共识声明

2022-08-18447
OAAI